CFN Media Interviews MariMed
December 13th, 2017
News, Top News
As more and more states legalize cannabis for medical and/or adult-use, there is a growing need for experts who can handle the myriad of issues and challenges new marijuana businesses will encounter. MariMed (OTCQB:MRMD) offers total solutions for both cultivators and dispensaries, all from professionals with a proven track record of success in the cannabis space. The company recently announced the purchase of edibles company Betty’s Eddies, a maker of an all-natural fruit chews, one of the most popular delivery methods currently on the market.
CFN Media recently sat down with MariMed Chief Operating Officer, Tim Shaw, to discuss the business’s consistent successes throughout the East Coast and beyond, as well as their dedication to consistent dosage for every single product sold.
Rachelle Gordon: How has MariMed grown since its founding in 2014?
Tim Shaw: It’s been an incredible experience. It started when a team of successful businessmen and cannabis experts came together and developed the nationally acclaimed Thomas Slater Compassion Center in Providence Rhode Island in 2012. At this facility, we developed best practices and operating procedures for cultivation, production, and dispensing. We realized we had the foundations for a new cannabis business model, so we developed a strategic plan to transfer this knowledge and intellectual property into a new entity to win cannabis licenses in other Eastern states and replicate the best and most compliant cannabis facilities in the country. That entity became MariMed, offering managed services for the design, development, finance, and optimization of medical cannabis cultivation, production, and dispensary facilities, coupled with licensing and distribution of MariMed branded precision dosed products.
The first implementation of the strategic plan was in Delaware where we developed a 50,000 square foot cultivation, production and dispensary facility for our client in Wilmington. Under our management, the medical cannabis program has been such a great success that in 2017 we developed and opened a second location for the client in Lewes. Subsequently, we have helped clients win licenses and develop cannabis facilities in Illinois, Nevada, Maryland, and Massachusetts. We have six facilties operating and five more under development.
MariMed is building a solid foundation for assets and revenue. We went from start up to $21 million in assets this year – a 150% increase over the previous year. In the first nine months of 2017, revenue was $4.5 million, an increase of 110% over same period in 2016, while EBITDA increased more than 300% to $1.36 million.
We recently developed a 100,000 square foot cultivation and production facility in Maryland. Planting has begun and products will be manufactured and sold starting in Q1 2018 throughout Maryland – to potentially 100 dispensaries that may open in the state’s new medical marijuana program in the next 12 months.
MariMed is poised for growth in 2018. We purchased a 137,500 square foot building in New Bedford, Massachusetts in November and are developing a 70,000 square foot cultivation and production facility that will be opening in Q1 2018. Under our client’s medical cannabis license, we will develop three dispensaries in other municipalities.
We’re also in the Illinois market with two stand-alone dispensaries. Our branded product line is being distributed into the wholesale market, where we’ve penetrated 52 of the 53 Illinois dispensaries. We are now in the Nevada market as well, where we have obtained our cultivation license. We just recently announced that we will be rolling out our branded products in Nevada and Maine.
RG: How do your branded products elevate MariMed’s presence in the cannabis market?
TS: In our seed to sale facilities on the East Coast, our team has been cultivating a full complement of cannabis strains and flowers in a variety of growing systems and methods. These facilities have their own labs, kitchens, production, packaging, and merchandising where we produce full lines of flowers, oils, salves, tinctures, and edibles.
With licensed patients at medical cannabis seed to sale facilities as “captive customers,” branding was not a priority. However, we saw an opportunity to build a brand of licensed products that would be novel in the larger wholesale markets out West. MariMed developed “Kalm Fusion,” a brand of unique, precision dosed, cannabis infused products. Our initlal products are Mari Melts, a thin dissolvable oral strip, Mari Mints/Chewable Tablets, Powdered Tincture a water soluable drink mix, and Kalm Korn, a buttery microwave popcorn. All these products are precision dosed with all-natural ingredients.
After successfully test marketing this brand in our Rhode Island and Delaware facilities, we soft launched them along with Betty’s Eddies, a mouthwatering, all-natural fruit chew product, into the wholesale Illinois market. Betty’s Eddies became the most popular product in the 51 open dispesaries. With this success, we tore up our rep agreeement and acquired the brand. We are now implementing our strategic plan to license the manufacturing and distribution of these hot products in all the legal states. We have just signed and launched our brands in Nevada, Maryland, and Maine. And there’s more to come in 2018
RG: How do you ensure precision dosing for end users?
TS: A major priority in our brand of products is both quality and consistency. The consistency is key – we’re solving an issue that plagued this industry as a whole. A ten milligram product should give you a relief of ten milligrams. No matter if you bought it in Massachusetts, California, or Illinois – you should get the same experience, similar to having two Tylenol. At the moment, that is tough to come by in our market. People are buying a ten-milligram brownie in one state, then they go to another location and that same ten milligrams puts them over the edge and makes for a bad experience.
We have developed or embraced the most stringent production, quality and security testing standards for distillation and dosing in the industry. All of our products go through rigorous testing, making sure each is precision dosed to within 5% of the amount stated on the package. That way my mother could have a ten milligram in Massachusetts, travel to Illinois and buy the same product without fear of overdoing it. We do a third-party lab test and back-check their testing with our own internal testing labs at each of our locations. If it comes out anything but perfect, we redo and re-test until it’s appropriately dosed.
RG: What differentiates MariMed from potential competitors in the space?
TS: We’ve been in this space as a team since 2012 with many of us working in the space prior to that, so- our sleeves are rolled all the way up. We already have a proven track record of operating and managing facilities in several states with thousands of patients. There are a lot of companies who tout the same abilities and the same know-how, but have never actually done it. We have. And through this we’ve made mistakes. We’re not the smartest guys in the world, but we’ve learned from our mistakes in order to make the company even more successful.
We have a proven track record of profitability as a fully reporting public company. We’ve successfully replicated our business model into multiple states. We’ve leveraged our years of experience so our customers, our clients, and our partners have all hit the ground running and prospered.
RG: Why should potential investors considering buying in to your company?
TS: MariMed’s professionals have multiple areas of expertise and a proven track record of success in cannabis and other businesses. Few companies in this market have our depth of expertise or a comparable track record. We are bringing professionalism into a hodge-podge industry. With MariMed, you are investing in a proven, tested company, with facilities and businesses that are thriving. We are profitable. We’re continuing to grow our client base, facilities and product lines. Our IP is scalable to every state.
Additionally, part of the upside to investing in MariMed is that we own the assets in all the locations where we establis facilities. We have hard assets; hard collateral to backup everything that we’re doing. We also have the intellectual property (IP) that we have created over the past four or five years. Our standard operating procedures (SOPs) are working documents that have been dialed in and are best practices in all aspects of the cannabis operation.
The investment momentum in now really starting. MariMed is focusing on attracting long-term strategic investors versus a short-term public investors. We’re being very careful with the bigger players that are coming in because it is about scaling. Once you’ve got the scaling element it attracts the acquisition purchase.
RG: What are your plans for expansion as the legal cannabis industry continues to grow?
TS: New facilities and product line expansion are our two high priorities for the end of this year and early 2018. MariMed is currently expanding into the Maryland and Massachusetts markets with new facilities and assisting clients in applying for facility licenses in Ohio and other states as they open applications. Additionally, we’ll be progressing on the expansion of our branded product lines nationally through licensing agreements.
As states close out their application processes for cannabis licenses, we’re going to be shifting our focus from application processes and building facilities to acquisition of existing companies. There are a lot of operations that are up and running and don’t know how to grow further.
Fortunately MariMed has the proven expertise that can maximize productivity while maintaining consistent product quality and potency, coupled with solid product R&D, marketing strategies and a rapidly expanding product distribution network to ensure continued growth on multiple levels nationwide.
This article was published by CFN Enterprises Inc. (OTCQB: CNFN), owner and operator of CFN Media, the industry’s leading agency and digital financial media network dedicated to the burgeoning CBD and legal cannabis industries. Call +1 (833) 420-CNFN for more information.
Follow Us on Social Media
About CFN Media Group
CFN Enterprises Inc. (OTCQB: CNFN) owns and operates CFN Media Group, the premier agency and financial media network reaching executives, entrepreneurs and consumers worldwide. Through its proprietary content creation, video library, and distribution via www.CannabisFN.com, CFN has built an extensive database of cannabis interest, assisting many of the world’s largest cannabis firms and CBD brands to build awareness and thrive. For more information, please visit www.cfnenterprisesinc.com.
Disclaimer: Matters discussed on this website contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time-to-time have a position in the securities mentioned herein and will increase or decrease such positions without notice. The Information contains forward-looking statements, i.e. statements or discussions that constitute predictions, expectations, beliefs, plans, estimates, or projections as indicated by such words as "expects", "will", "anticipates", and "estimates"; therefore, you should proceed with extreme caution in relying upon such statements and conduct a full investigation of the Information and the Profiled Issuer as well as any such forward-looking statements. Any forward looking statements we make in the Information are limited to the time period in which they are made, and we do not undertake to update forward looking statements that may change at any time; The Information is presented only as a brief "snapshot" of the Profiled Issuer and should only be used, at most, and if at all, as a starting point for you to conduct a thorough investigation of the Profiled Issuer and its securities and to consult your financial, legal or other adviser(s) and avail yourself of the filings and information that may be accessed at www.sec.gov, www.pinksheets.com, www.otcmarkets.com or other electronic sources, including: (a) reviewing SEC periodic reports (Forms 10-Q and 10-K), reports of material events (Form 8-K), insider reports (Forms 3, 4, 5 and Schedule 13D); (b) reviewing Information and Disclosure Statements and unaudited financial reports filed with the Pink Sheets or www.otcmarkets.com; (c) obtaining and reviewing publicly available information contained in commonlyknown search engines such as Google; and (d) consulting investment guides at www.sec.gov and www.finra.com. You should always be cognizant that the Profiled Issuers may not be current in their reporting obligations with the SEC and OTCMarkets and/or have negative signs at www.otcmarkets.com (See section below titled "Risks Related to the Profiled Issuers, which provides additional information pertaining thereto). For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity-based compensation in the companies it writes about, or a combination of the two. For full disclosure, please visit: https://www.cannabisfn.com/legal-disclaimer/. A short time after we acquire the securities of the foregoing company, we may publish the (favorable) information about the issuer referenced above advising others, including you, to purchase; and while doing so, we may sell the securities we acquired. In addition, a third-party shareholder compensating us may sell his or her shares of the issuer while we are publishing favorable information about the issuer. Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. CFN Media Group, which owns CannabisFN, is not registered with any financial or securities regulatory authority, and does not provide nor claims to provide investment advice or recommendations to readers of this release. CFN Media Group, which owns CannabisFN, may from time to time have a position in the securities mentioned herein and will increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice and that of their own professional advisers. CFN Media Group, which owns CannabisFN, may be compensated for its Services in the form of cash-based and/or equity- based compensation in the companies it writes about, or a combination of the two. For full disclosure please visit: https://www.cannabisfn.com/legal-disclaimer/.